Elevation Oncology Inc (NASDAQ:ELEV) price on Thursday, March 20, fall -41.82% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.28.
A look at the stock’s price movement, the close in the last trading session was $0.48, moving within a range at $0.241 and $0.3196. The beta value (5-Year monthly) was 1.382. Turning to its 52-week performance, $5.83 and $0.41 were the 52-week high and 52-week low respectively. Overall, ELEV moved -57.24% over the past month.
Elevation Oncology Inc’s market cap currently stands at around $16.46 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ELEV is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend ELEV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ELEV’s current price about -44.89% and -54.04% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 22.51, while 7-day volatility ratio is 13.10% and 10.98% in the 30-day chart. Further, Elevation Oncology Inc (ELEV) has a beta value of 1.41, and an average true range (ATR) of 0.06. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $8 and high of $10. Looking at the price targets, the low is -2757.14% off current price level while to achieve the yearly target high, price needs to move -3471.43%. Nonetheless, investors will most likely welcome a -3114.29% jump to $9 which is the analysts’ median price.
If we refocus on Elevation Oncology Inc (NASDAQ:ELEV), historical trading data shows that trading volumes averaged 2.34 over the past 10 days and 2.22 million over the past 3 months. The company’s latest data on shares outstanding shows there are 59.13 million shares.
The 12.07% of Elevation Oncology Inc’s shares are in the hands of company insiders while institutional holders own 56.02% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.56 million on 2025-02-28, giving us a short ratio of 6.75. The data shows that as of 2025-02-28 short interest in Elevation Oncology Inc (ELEV) stood at 1526.0000000000002 of shares outstanding, with shares short falling to 8.77 million registered in 2025-01-31. Current price change has pushed the stock -50.59% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ELEV stock continues to rise going into the next quarter.
